:::回首頁English網站導覽常見問答聯絡我們FB粉絲專頁  
本院簡介 研究單位 技術移轉 研究資源 圖書館 訊息公告 院內網站
 
::: 首頁>

* * *
*
 
Hu Yung-Chih

胡勇誌 助研究員
感染症與疫苗研究所
連絡電話:037 246166 ext. 37708
傳真電話:037 583009
E-mail:alanhu@nhri.org.tw

學歷


2000/01 - 2004/12     Ph.D., Chemical Engineering, Imperial College London, London, U.K.
1996/09 - 1999/05     M.Phil., Chemical Engineering, The University of Birmingham, Birmingham. U.K.
1988/09 - 1994/06     B.S., Chemical Engineering, National Taipei University of Technology, Taipei, Taiwan

經歷

2012/02 - present     Joint Assistant Professor, Biotechnology Center, National Chung Hsing University, Taichung, Taiwan
2011/10 - present     Assistant Investigator, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan
2011/07 - 2011/09     Manager, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan
2007/09 - present     Adjunct assistant professor, Department of Chemical Engineering and Materials Science, Yuan Ze University, Chungli, Taiwan
2007/07 - 2009/02     Adjunct assistant professor, Graduate school of Biotechnology, National Taipei University of Technology, Taipei, Taiwan
2005/07 - 2011/06     Postdoctoral Fellow, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan
1999/08 - 1999/12     Underwriter, New Insurance, Shin-Kon Property Insurance Company, Taipei, Taiwan

行政兼職

 



Research Interests

 

Dr. Hu has more than 10 years knowledge in the bioprocess technology development, including animal cell culture process technology using CHO, MDCK and Vero cell-lines, and good experience in large-scale, high-cell-density fermentation technology, and downstream purification processes technology. Extensive background in bioreactor design, process controls, equipment validation, facility design and planning. He also has hands-on knowledge of cGMP requirements (FDA/WHO guidelines) and compliance regulations for biological products. Currently, Dr. Hu is an assistant investigator and also a program leader for the development of Influenza vaccines in the National Institute of Infectious Diseases and Vaccinology. In this position, He is leading a team of technicians and research assistants for the development of an Influenza H5N1 vaccine production process using my newly developed cell culture technology - a high cell-yield and animal-component-free culture media. In addition, Dr. Hu also involved with technology support and development of disposable bioreactor systems for other vaccine projects. In the past few years He has successfully completed a number of projects with Taiwan government agencies as well as external biopharmaceutical companies. With these on job training, Dr. Hu is able to acquire in-depth knowledge and skill in different part of the bioprocess and eventually developed a broad skill set for the biologics manufacturing.


Research Activities & Accomplishment

 

Achievements in the vaccine R&D center:
  • Established the P2+ lab for H5N1 emerging vaccine production.
  • Finished planning, design and commissioning of pilot plant facility for the production of influenza H5N1vaccine production.
  • Established the vaccine production capability from 2.2 L to 150L bioreactors.
  • Established a bioprocess development platform for H1N1, H5N1 and EV71 viral vaccines.
  • Developed a new downstream purification process for influenza viral production.


Publications

 

Journal papers:

  1. YF Tseng, TC Weng, CC Lai, PL Chen, MS Lee and AY Hu (2017). A fast and efficient purification platform for cell-based influenza viruses by flow-through chromatography. Submitted to Vaccine (in press). (IF 3.41)
  2. CC Liu, SC Wu, SR Wu, HY Lin, MS Guo, AY Hu, YH Chow, JR Chiang, DB Shieh, P Chong (2017). Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture. Submitted to Vaccine (in press). (IF 3.41)
  3. MY Chia, AY Hu, YF Tseng, TC Weng, CC Lai, JY Lin, PL Chen, YF Wang, SR Chao, JY Chang, YS Hwang, CT Yeh, CP Yu, YC Chen, IJ Su, MS Lee (2015). Evaluation of MDCK Cell-Derived Influenza H7N9 Vaccine Candidates in Ferrets. PLoS One, Vol. 10, No.3, pp. e0120793. (IF 4.35) (The first and second authors had equal contribution).
  4. CW Lin, CY Chang, WL Chen, SC Lin, CC Liao, JY Chang, CC Liu, AY Hu, TC Lu, AH Chou, SC Wu, P Chong, MH Huang (2013). Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV. Human Vaccines and Immunotherapeutics. Vol.9, No. 11, pp. 2378-2385. (IF 3.14)
  5. A Hilal-Alnaqbi, AY Hu, Z Zhang, M Al-Rubeai (2013). Growth, metabolic activity, and productivity of immobilized and freely suspended CHO cells in perfusion culture. Biotechnology and applied biochemistry. Vol.60, No. 4, pp. 436-445. (IF 1.322)
  6. AH Chou, CC Liu, CP Chang, MS Guo, SY Hsieh, WH Yang, HJ Chao, CL Wu, JL Huang, MS Lee, AY Hu, SC Lin, YY Huang, MH Hu, YH Chow, JR Chiang, JY Chang, P. Chong (2012). Pilot Scale Production of Highly Efficacious and Stable Enterovirus 71 Vaccine Candidates. PLoS One, Vol. 7, No.4, pp.e34834. (IF 4.35))
  7. Lee, MS and AY Hu, AY (2012). A cell-based backup to speed up pandemic influenza vaccine production. Trends in Microbiology. 2012 Jan 16;Article in Press (IF 7.5).
  8. YF Tseng, AY Hu, ML Huang, WZ Yeh, TC Weng, YS Chen, MS Lee (2011). Adaptation of High-growth Influenza H5N1 Vaccine Virus in Vero Cells: implications for pandemic preparedness. PLoS One, Vol. 6, No.10, pp.e24057.(IF 4.351) (The first and second authors had equal contribution).
  9. AY Hu, YF Tseng, TC Weng, CCLiao, J Wu, AH Chou, HJ Chao, A Gu, Janice Chen, SC Lin, S Hsiao, SC Wu andP Chong (2011). The Production of MDCK cell-derived inactivated influenza H5N1 vaccines using serum-free medium. PLoS One, Vol. 6, No.1, pp.e14578.(IF 4.351).
  10. MH Huang, SC Lin, CH Hsiao, HJ Chao, HR Yang, CC Liao, PW Chuang, HP Wu, CY Huang, CH Leng, SJ Liu, HW Chen, AH Chou, AY Hu, Pele Chong. (2010) Emulsified Nanoparticles Containing Inactivated Influenza Virus and CpG Oligodeoxynucleotides Critically Influences the Host Immune Responses in Mice.  PLoS One, Vol. 5, No.8, pp.e12279.(IF 4.351)
  11. AY Hu, TC Weng, YF Tseng, YS Chen, CH Wu, S Hsiao, AH Chou, HJ Chao, A Gu, SC Wu, P Chong and MS Lee (2008). Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines. Vaccine,vol. 26, no.45, pp.5736-5740.(IF: 3.616)
  12. AY Hu and DC Stuckey (2007). Activated Carbon Addition to a Submerged Anaerobic Membrane Bioreactor: Effect on Performance, Transmembrane Pressure, and Flux. Journal of Environmental Engineering, Vol. 133, No.1, pp.73-80. (IF: 1.048)
  13. AY Hu and DC Stuckey (2006). Treatment of Dilute Wastewaters Using a Novel Submerged Anaerobic Membrane Bioreactor. Journal of Environmental Engineering, vol. 132, no.2, pp.190-198. (IF: 1.048)
  14. S Aquino, AY Hu, A Akram and DC Stuckey (2006) Characterization of Dissolved Compounds In Submerged Anaerobic Membrane Bioreactors (SAMBRs). Journal of Chemical Technology and Biotechnology, vol. 81, no.12, pp.1894-1904. (IF: 2.045)
Book/chapters:
  1. 胡勇誌、周愛湘、蕭佳欣、莊再成 (2010). 全球流感疫苗技術發展與市場趨勢。 2010生物應用工程年鑑
  2. 胡勇誌 (2009). 疫苗製程細胞培養生物反應器操作之經驗分享。國家衛生研究院電子報,第325期。
  3. 胡勇誌 ; 江正榮 ; 劉家齊 ; 張瑞原 ; 林小瑜 ; 賽逸昕 ; 林素貞 ; 郭孟欣 ; 張正鵬 ; 李敏西 ; 莊再成 (2009)。腸病毒疫苗製程研發近況。臨床試驗中英文季刊,第4卷第2季,第 19-26
  4. 蕭佳欣、胡勇誌、周愛湘、莊再成 (2009). 預防勝於治療流感疫苗的研製現況科學月刊7月號,第509-513頁。科學月刊雜誌社,台北,台灣。


Lab Member

姓 名 職 稱 分機 E-mail
曾才騰 博士後研究學者 37720
鄭郁潔 博士後研究學者 37714
曾郁雰 博士班研究生(休學中) 37737
賴嘉俊 博士班研究生(清華大學) 37737
翁彩娟 研究助理 37737
莊峻翔 碩士班研究生(清華大學) 37737
陳品妏 計劃助理 37737
蔡欣憶 計劃助理 37737
陸嘉駿 計劃助理 37737
周欣怡 計劃助理 37737

更新日期:2017-10-20

回上一層

 

*
* * *
     
  政策與免責聲明 | 財團法人國家衛生研究院版權所有
竹南院區:苗栗縣竹南鎮 35053 科研路35號 -- 電話: +886-37-206-166
台北辦事處:台北市南港區 11503 園區街3號10樓(南港軟體園區F棟) -- 電話: +886-2-2653-4401
台南院區:台南市北區 70456 勝利路367號(統一健康研究大樓) -- 電話: +886-6-700-0123
各單位分機代表號
電子信箱:webmaster@nhri.org.tw
FB粉絲專頁:財團法人國家衛生研究院@NHRI.TW